1. Scrip

The Inevitable Is Coming: Price Increases, Starting With Pfizer

 
• By Jessica Merrill

Drug makers are planning for annual price increases, but with the industry in President Trump's crosshairs it remains to be seen if 2019 price hikes will be more modest than in the past. Pfizer confirmed plans to raise prices, but only on 10% of its portfolio.

Rising-Prices_1200.jpg

As 2019 approaches, a big question is how drug makers will handle annual US price increases, usually taken on marketed drugs in January, in an increasingly hostile political environment. Even with the industry in President Trump's crosshairs on the issue of high drug prices, some amount of drug price hikes seems inevitable given how reliant the industry is on them to drive top-line growth.

Pfizer confirmed Nov. 16 that it is raising prices on some of its medicines, although the announcement wasn't particularly surprising given that CEO Ian Read had indicated as much during...

More from Drug Pricing

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.